Prognostic significance of plasma osteopontin level in breast cancer patients

[1] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1. 2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer [available from], <http:// www.globocan.iarc.fr/factsheets/cancers/breast. asp>; 2010 [accessed on 24.09.2012].Search in Google Scholar

[2] The National Cancer Registry Program of Egypt (NCRPE). Reports and Statistics: Aswan, Damietta & El-Minia [available from], <http://www. cancerregistry.gov.eg/reports.aspx> [accessed 5.09.2012].Search in Google Scholar

[3] The Gharbiah Population-based Cancer Registry (GPCR). Cancer in Egypt, Gharbiah [available from], <http://www.emro.who.int/ncd/pdf/cancer_ registry_Egypt.pdf>; 2007 [accessed 5.09.2012].Search in Google Scholar

[4] Ali-eldin N. Cancer statistics 2002-2007: Preliminary report [online], <http://www.nci.cu.edu.eg/lectures/ Cancer_statistics.pdf> [accessed 5.09.2012].Search in Google Scholar

[5] Clohisy JC, Frazier E, Hirayama T, Abu-Amer Y. RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. J Orthop Res. 2003; 21: 202-212.10.1016/S0736-0266(02)00133-XSearch in Google Scholar

[6] Munday GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2(8): 584-93.10.1038/nrc86712154351Search in Google Scholar

[7] Bohn LO, Nasir I, Brufsky A, Tseng GC, Bhargava R. Biomarker profile in breast carcinomas presenting with bone metastasis. Int J Clin Exp Pathol. 2010; 3(2): 139-146.Search in Google Scholar

[8] Koizumi M, Ogata E. Bone metabolic markers as gauges of metastasis to bone: a review. Annals of Nuclear Medicine. 2002; 16 (3): 161-168.10.1007/BF0299629612126040Search in Google Scholar

[9] Bellahcene A, Castronovo V, Ogbureke K U, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): Multifunctional proteins in cancer. Nat Rev Cancer. 2008; 8: 212-226.10.1038/nrc2345248412118292776Search in Google Scholar

[10] Rodrigues L, Jose´ A, Teixeira F, Schmitt L, Marie P. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(6): 1087-97.10.1158/1055-9965.EPI-06-100817548669Search in Google Scholar

[11] Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 2010; Feb: 10(1): 71-81.10.2174/156652410791065381686933820205680Search in Google Scholar

[12] Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF: The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med. 2001; 1: 621-632.10.2174/156652401336333911899236Search in Google Scholar

[13] Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001; 7: 4060-6.Search in Google Scholar

[14] Senger DR, Perruzzi CA, Gracey CF, Papadopoulos A, Tenen DG. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res. 1988; 48: 5770-4.Search in Google Scholar

[15] Hemant S, Diosdado SB, Katia ST, Fraces PO, Alan BT, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clinical Cancer Research 1997; 3: 605-611.Search in Google Scholar

[16] Vivien HC, Alan BT, Judith AW, Pieter HA, Car OP, et al. Assessment of Osteopontin in early breast cancer, correlative study in a randomized clinical trial. Breast Cancer Research. 2014;16R8 (10): 1188.10.1186/bcr3600397873624451146Search in Google Scholar

[17] Vivien HC, Gordon S D, Alan BT, Sylvia MW, Katia ST, Anna T et al. Serial Plasma Osteopontin Levels Have Prognostic Value in metastatic breast cancer, Clin Cancer Res. 2006; 12: 3337-3343.10.1158/1078-0432.CCR-05-235416740755Search in Google Scholar

[18] Kim JH, Skates SJ, Uede T, Kohri K, Tozawa K, Okamura T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002; 287: 1671-9.10.1001/jama.287.13.167111926891Search in Google Scholar

[19] Saeki Y, Mima T, Ishii T, Ogata A, Ohshima S, Kobayashi H et al. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br J Haematol. 2003; 123: 263-70.10.1046/j.1365-2141.2003.04589.x14531907Search in Google Scholar

[20] Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone refractory prostate carcinoma. Cancer. 2002; 95: 506-12.10.1002/cncr.1070912209742Search in Google Scholar

[21] Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003; 9: 59-67.Search in Google Scholar

[22] Ang C, Chambers AF, Tuck AB, Winquist E, Izawa JI. Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. Br J Urol Int. 2005; 96: 803-5.10.1111/j.1464-410X.2005.05716.x16153205Search in Google Scholar

[23] Neill P, Fadi J, Wen J, Kefah M. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anti-Cancer Res. 2008;28: 4105-10.Search in Google Scholar